Aetna is planning to sell its Medicare Part D plan to WellCare Health Plans. The transaction is contingent on regulatory approval of Aetna’s acquisition of CVS. The insurer is hoping the proposed sale will help the $69 billion deal for the drugstore chain get approval. (CNBC)

Drug companies have spent $2.8 billion on TV advertising this year, according to iSpot.tv. The pharma industry, along with tech and finance, drove a 6% jump in ad spending in 2018, according to media advisory firm Magna Global. (BioPharma Dive)

AstraZeneca has been accused of using nurses to promote three of its top-selling drugs. A newly unsealed lawsuit from two former employees of a firm AstraZeneca worked with said the company hired nurses to push drugs under the guise of education or counseling. (Reuters)

U.S. and Cuban research institutes have teamed up to bring new cancer treatments stateside. The venture, the first U.S.-Cuba partnership in biotech, will be a three-year partnership between Roswell Park Cancer Institute in Buffalo, New York, and Cuba’s Center for Molecular Immunology. The goal is to bring a Cuban-developed lung cancer treatment to the U.S. (Reuters)

Alnylam is moving forward with its second gene silencing rare disease treatment. The company reported positive results from an interim study of givosiran. Alnylam is planning to file for accelerated approval this year. The first “gene silencing” drug, or a treatment that uses RNA interference that silences disease-causing genes, was also developed by Alnylam and approved in August. (STAT)